Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRui LiuShanxi Agricultural UniversityZFZhonghua FuNorthwestern Polytechnical UniversityFYFan YangHenan University of Science and Technology

Discussion

Loading...

Member takes

Implication

Retrospective analysis shows improved outcomes in B-NHL with glofitamab bridging therapy, suggesting enhanced CAR-T efficacy.

Key Points

  • Complete responses were observed in 3 patients after glofitamab before CAR-T infusion, indicating promising treatment potential.
  • Cytokine release syndrome occurred in 78% of patients post-CAR-T, all grade 1-2, highlighting manageable side effects.
  • Leukapheresis was performed prior to glofitamab administration to facilitate CAR-T manufacturing in patients.
  • Burkitt lymphoma and mantle cell lymphoma were among the histologic subtypes involved in this bridging therapy study.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8echttps://doi.org/10.1182/blood-2025-7259
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.2025 · 1 citations
  2. 2Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma2025
  3. 3Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab2025
  4. 4Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL2025
  5. 5Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma2025 · 1 citations